

ABOUT GENBIOMA

Spanish biotechnology startup specialized in the development of **clinically-validated food ingredients based on microbiome science**, to prevent and manage **metabolic disorders** such as diabetes, obesity, and dyslipidemia. Our mission is to **prevent metabolic disorders through microbiome innovation**, developing evidence-based probiotics and postbiotics that restore metabolic balance naturally. Genbioma operates a **platform-based model** that turns microbiome science into **clinically validated, industrially scalable ingredients and nutraceuticals** for metabolic health. Our **rapid screening platform** combining *C. elegans*, metagenomics, and metabolomics, enables **fast, cost-efficient development** and **industrial scale-up** of novel probiotics & postbiotics.

TECHNOLOGY & IP

A unique screening platform: Cuts cost, risk and time to market

- Array of validated assays for glucose, lipid and cardiovascular metabolism using *C. elegans* model.
- Integrated metagenomics & metabolomics to unveil mode-of-action early.
- Regulatory filters baked in: Safety, IP and regulatory checkpoints for early candidate de-selection.
- Human Validation: Real-World Evidence & Clinical Trials



FLAGSHIP PRODUCT – Pa1c®HI POSTBIOTIC

pA1c®HI is the **first clinically proven postbiotic** that improves glycemic control.

- Derived from our patented strain pA1c®, it offers **heat stability, 3-year shelf life, and daily low-dose efficacy**.
- **Clinical evidence on glucose control** in HbA1c in T2 Diabetes and PreDiabetes.
- **2 patent families extended to 35 countries**
- **+10 positive preclinical studies** (*C. elegans* and rodents)
- **+2 Positive human studies** (Clinical Trials & Real World)
- **+10 publications** in Q1 Sci. journals
- MoA: reduces **insulin resistance**, activates the **GLP-1 pathway** and **rebalances microbiota** composition.
- Regulatory status: **EFSA QPS / FDA GRAS**.
- **Worldwide trademark protection**, including EU, US, UK, JP, AI.



MARKET & PIPELINE

We create **dual-market ingredients for nutraceuticals and functional foods**, offering both **bulk supply** and **finished formulations**.

Partner-Centric B2B Model Accelerating Market Access



Active Ingredient
in Bulk Powder



Ready-to-Market capsules



Innovative formats

CONTACT

www.genbioma.com

www.linkedin.com/company/genbioma

Iñaki Iturria, PhD

Business Development Manager

iiturria@genbioma.com